TherapeuticsMD Inc（TXMD）財務資料TXMDTherapeuticsMD Inc

TherapeuticsMD Inc (TXMD) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Mayne Pharma, accounting for 5951.5% of total sales, equivalent to $68.56M. Other significant revenue streams include Theramex and License revenue. Understanding this composition is critical for investors evaluating how TXMD navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, TherapeuticsMD Inc maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -92.41%, while the net margin is 18.87%. These profitability ratios, combined with a Return on Equity (ROE) of -1.08%, provide a clear picture of how effectively TXMD converts its operational activities into shareholder value.

In the context of the broader market, TXMD competes directly with industry leaders such as AYTU and ATOS. With a market capitalization of $19.67M, it holds a significant position in the sector. When comparing efficiency, TXMD's gross margin of 100.00% stands against AYTU's 59.90% and ATOS's N/A. Such benchmarking helps identify whether TherapeuticsMD Inc is trading at a premium or discount relative to its financial performance.

TherapeuticsMD has shown some improvement in its financials, with a gross margin of 100% and a current ratio of 3.22, indicating good liquidity. However, the company has also faced net income losses in several quarters, including a loss of $619,000 in Q4 2025, which raises concerns about its profitability.